Bionexus Gene Lab Stock Price on November 29, 2024
| BGLC Stock | USD 0.23 0.01 4.17% |
Below is the normalized historical share price chart for BioNexus Gene Lab extending back to September 16, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of BioNexus Gene stands at 0.23, as last reported on the 2nd of December, with the highest price reaching 0.24 and the lowest price hitting 0.23 during the day.
If you're considering investing in BioNexus Stock, it is important to understand the factors that can impact its price. BioNexus Gene Lab secures Sharpe Ratio (or Efficiency) of -0.23, which signifies that the company had a -0.23% return per unit of risk over the last 3 months. BioNexus Gene Lab exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioNexus Gene's Mean Deviation of 2.88, risk adjusted performance of (0.19), and Standard Deviation of 3.79 to double-check the risk estimate we provide.
The current year's Issuance Of Capital Stock is expected to grow to about 6 M, whereas Other Stockholder Equity is forecasted to decline to (4.7 M). . At present, BioNexus Gene's Price To Book Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Fair Value is expected to grow to 0.91, whereas Price To Sales Ratio is forecasted to decline to 0.82. BioNexus Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 16th of September 2020 | 200 Day MA 0.5128 | 50 Day MA 0.3651 | Beta 1.866 |
BioNexus |
Sharpe Ratio = -0.2273
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BGLC |
Estimated Market Risk
| 3.8 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.86 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioNexus Gene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioNexus Gene by adding BioNexus Gene to a well-diversified portfolio.
Price Book 0.4427 | Enterprise Value Ebitda 629.5269 | Price Sales 0.473 | Shares Float 13.8 M | Earnings Share (0.06) |
Related Headline
Alto Ingredients Headline on 29th of November 2024
Alto Ingredients, Inc. to Cold Idle Magic Valley Facility at... by gurufocus.com
Search for Stocks, ETFs, Indices, Insiders, Investing Gurus and Futures on Gurufocus.com.
BioNexus Gene Valuation on November 29, 2024
It is possible to determine the worth of BioNexus Gene on a given historical date. On November 29, 2024 BioNexus was worth 0.24 at the beginning of the trading date compared to the closed value of 0.23. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of BioNexus Gene stock. Still, in general, we apply an absolute valuation method to find BioNexus Gene's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioNexus Gene where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against BioNexus Gene's related companies.
| Open | High | Low | Close | Volume | |
| 0.24 | 0.24 | 0.23 | 0.24 | 69,900 | |
11/29/2024 | 0.24 | 0.24 | 0.23 | 0.23 | 49,100 |
| 0.24 | 0.24 | 0.23 | 0.23 | 0.00 |
| Backtest BioNexus Gene | | | BioNexus Gene History | | | BioNexus Gene Valuation | Previous | Next |
BioNexus Gene Trading Date Momentum on November 29, 2024
| On December 02 2024 BioNexus Gene Lab was traded for 0.23 at the closing time. The top price for the day was 0.24 and the lowest listed price was 0.23 . There was no trading activity during the period 0.0. Lack of trading volume on December 2, 2024 did not affect price variability. The overall trading delta against the current closing price is 4.35% . |
BioNexus Gene Lab Fundamentals Correlations and Trends
By evaluating BioNexus Gene's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among BioNexus Gene's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. BioNexus financial account trend analysis is a perfect complement when working with valuation or volatility modules.About BioNexus Gene Stock history
BioNexus Gene investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for BioNexus is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in BioNexus Gene Lab will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing BioNexus Gene stock prices may prove useful in developing a viable investing in BioNexus Gene
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 15.9 M | 12.1 M | |
| Net Income Applicable To Common Shares | 864.3 K | 907.5 K |
BioNexus Gene Quarterly Net Working Capital |
|
BioNexus Gene Stock Technical Analysis
BioNexus Gene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
BioNexus Gene Period Price Range
Low | December 2, 2024
| High |
0.00 | 0.00 |
BioNexus Gene Lab cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
BioNexus Gene December 2, 2024 Market Strength
Market strength indicators help investors to evaluate how BioNexus Gene stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioNexus Gene shares will generate the highest return on investment. By undertsting and applying BioNexus Gene stock market strength indicators, traders can identify BioNexus Gene Lab entry and exit signals to maximize returns
BioNexus Gene Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for BioNexus Gene's price direction in advance. Along with the technical and fundamental analysis of BioNexus Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of BioNexus to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.19) | |||
| Jensen Alpha | (0.99) | |||
| Total Risk Alpha | (1.62) | |||
| Treynor Ratio | (32.98) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |